Company Overview of PhaseRx, Inc.
PhaseRx, Inc. is developing RNA nanomedicines for the treatment of orphan liver disease. Its SMARTT Polymer Technology provides the ability to deliver messenger RNA therapeutics to selected tissues in vivo, thereby unlocking the value of mRNA as a therapeutic modality. The company was incorporated in 2006 and is based in Seattle, Washington.
410 West Harrison Street
Seattle, WA 98119
Founded in 2006
Key Executives for PhaseRx, Inc.
Co-Founder, Chief Executive Officer, President and Director
Co-Founder, Chief Scientific Officer and Director
Compensation as of Fiscal Year 2015.
PhaseRx, Inc. Key Developments
PhaseRx, Inc. Presents at Boston CEO Conference, May-27-2015 04:00 PM
Apr 16 15
PhaseRx, Inc. Presents at Boston CEO Conference, May-27-2015 04:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Robert W. Overell, Co-Founder, Chief Executive Officer, President and Director.
PhaseRx, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 01:40 PM
Dec 3 14
PhaseRx, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 01:40 PM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103, United States. Speakers: Robert W. Overell, Co-Founder, Chief Executive Officer, President and Director.
PhaseRx, Inc. Appoints Michael Houston as Vice President, Therapeutics Development
Jan 10 14
PhaseRx, Inc. announced the appointment of Michael Houston, Ph.D., as its Vice President, Therapeutics Development. Dr. Houston brings more than two decades of experience in the manufacturing and development of peptide and oligonucleotide-based therapeutics to PhaseRx. He has directed numerous programs ranging from research to GMP manufacture of clinical trials materials, including nanoparticle-based delivery vehicles for siRNAs. In this new position, Dr. Houston will lead PhaseRx's therapeutics program, which focuses on the advancement of its SMARTT Polymer Technology(R) mRNA nanoparticles. Dr. Houston joins PhaseRx from Marina Biotech where he served as Vice President, Chemistry and Formulations and focused on the development of siRNAS and single stranded oligonucleotides. He has also served at Ascent Therapeutics as Vice President, Preclinical Chemistry and CMC; at MDRNA, Inc. as Vice President, Chemistry & Formulations; and at Nastech Pharmaceuticals as Senior Director, Chemistry and Formulations.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|